Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics' Q4, FY 2010 Revenues Rise

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Response Genetics today reported that its fourth-quarter revenues jumped 88 percent as sales for its ResponseDX genetic tests rose sharply year over year.

The Los Angeles-based genetic test maker reported total revenues of $6.4 million for the three-month period ended Dec. 31, compared to $3.4 million for the fourth quarter of 2009. Sales for its ResponseDX genetic tests jumped 82 percent to $3.1 million from $1.7 million.

Response Genetics also trimmed its net loss to $1.1 million, or $.06 per share, from $1.7 million, or $.11 per share, for Q4 2009.

Its R&D spending declined to $332,081 from $579,262, while its SG&A expenses jumped to $4.2 million from $2.7 million.

For full-year 2010, Response Genetics posted revenues of $21.3 million, up 135 percent from $9.1 million for 2009. Sales for its ResponseDX tests rose 242 percent to $11.3 million for the year.

The firm posted a net loss of $4.7 million, or $.26 per share, compared to a net loss of $9.3 million, or $.70 per share, for FY 2009.

Its R&D spending for the year fell to $1.6 million from $2.3 million, while its SG&A spending climbed to $14.1 million from $9.6 million.

Response Genetics finished the year with $4.1 million in cash and cash equivalents.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.